New drug for recurrent and newly diagnosed glioblastoma
Part of Brain & nervous system, Cancer clinical trials.
This trial tests an experimental oral drug called CT-179, which targets a protein involved in brain tumor growth. It may help people with glioblastoma, a type of brain cancer, when standard treatments have not worked or as part of initial treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have a confirmed diagnosis of glioblastoma (a type of brain cancer).
- You need to be fairly independent in daily activities (Karnofsky score of 70 or higher).
- Your liver, kidney, and blood counts must be within acceptable levels.
- You must be able to swallow pills and not have any stomach problems that would affect drug absorption.
- You cannot have had certain recent treatments or medical conditions (e.g., no bleeding in the brain, no active hepatitis B or C, no more than 4 mg/day of dexamethasone within the last week).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1/2 trial tests two experimental treatments delivered through a thin catheter placed in the brain for people with newly diagnosed glioblastoma (GBM). The goal is to see whether the treatment can be given safely and whether it may shrink or control the tumor after standard chemotherapy and radiation.
This trial tests a new drug called BL-B01D1 for people whose glioblastoma has come back after standard treatment. The goal is to see if the drug can help control the tumor.
This trial tests a new drug (KH617) for people with glioblastoma that has returned after initial treatment. It may offer a new option for those whose tumor type is not helped by standard chemotherapy.
This trial tests an investigational drug called pumitamig (also known as BNT327) in people whose glioblastoma has come back after standard treatment with radiation and temozolomide. The goal is to see if the drug is safe and whether it can help slow or stop tumor growth.
This trial tests whether customized drug screening on your tumor cells can help doctors choose the best treatment for you. Your tumor cells will be grown in the lab and tested against different drugs to find what works best, combined with short-course radiation therapy.
This trial tests whether testing drugs on your tumor cells in a lab can help find the best treatment for you. It is for people with a specific type of glioblastoma that has not been treated yet.
Hear when a new Recurrent Glioblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.